留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

伊文思兰改造多肽用于诊疗一体化的临床转化研究进展

刘清杏 陈小元 朱朝晖

刘清杏, 陈小元, 朱朝晖. 伊文思兰改造多肽用于诊疗一体化的临床转化研究进展[J]. 协和医学杂志, 2022, 13(2): 180-186. doi: 10.12290/xhyxzz.2021-0764
引用本文: 刘清杏, 陈小元, 朱朝晖. 伊文思兰改造多肽用于诊疗一体化的临床转化研究进展[J]. 协和医学杂志, 2022, 13(2): 180-186. doi: 10.12290/xhyxzz.2021-0764
LIU Qingxing, CHEN Xiaoyuan, ZHU Zhaohui. Clinical Translational Research of Evans Blue Modified Peptides Used for Theranostics[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 180-186. doi: 10.12290/xhyxzz.2021-0764
Citation: LIU Qingxing, CHEN Xiaoyuan, ZHU Zhaohui. Clinical Translational Research of Evans Blue Modified Peptides Used for Theranostics[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 180-186. doi: 10.12290/xhyxzz.2021-0764

伊文思兰改造多肽用于诊疗一体化的临床转化研究进展

doi: 10.12290/xhyxzz.2021-0764
基金项目: 

国家自然科学基金 81871392

首都卫生发展科研专项 2018-1-4011

中国医学科学院医学与健康科技创新工程 2021-I2M-1-016

中国医学科学院临床转化基金 2019XK320032

详细信息
    通讯作者:

    陈小元,E-mail:chen.shawn@nus.edu.sg

    朱朝晖,E-mail:zhuzhh@pumch.cn

  • 中图分类号: R445; R-1

Clinical Translational Research of Evans Blue Modified Peptides Used for Theranostics

Funds: 

National Natural Science Foundation of China 81871392

The Capital Health Development Scientific Research Project 2018-1-4011

CAMS Innovation Fund for Medical Sciences 2021-I2M-1-016

CAMS Clinical and Translational Medicine Research Fund 2019XK320032

More Information
  • 摘要: 肽受体放射性核素治疗(peptide receptor radionuclide therapy,PRRT)是利用放射性核素标记的多肽与肿瘤细胞表面受体进行特异性结合,从而发挥射线的辐射生物效应。近年来,如何进一步提高PRRT药物的疗效一直是国际研究热点。伊文思兰(Evans blue)可与血浆中的白蛋白可逆性结合,故将伊文思兰加入多肽结构可延长放射性药物在血液中的清除时间,改变药代动力学,提高PRRT疗效。本文将围绕伊文思兰改造多肽用于诊疗一体化的临床转化研究进行概述。
    作者贡献:刘清杏负责文献查阅及初稿撰写;陈小元、朱朝晖负责选题设计,指导论文修订。
    利益冲突:所有作者均声明不存在利益冲突
  • 图  1  伊文思兰分子式

  • [1] Sand KM, Bern M, Nilsen J, et al. Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics[J]. Front Immunol, 2014, 5: 682.
    [2] Liu Z, Chen X. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy[J]. Chem Soc Rev, 2016, 45: 1432-1456. doi:  10.1039/C5CS00158G
    [3] Evans HM, Schulemann W. The Action of Vital Stains Belonging to the Benzidine Group[J]. Science, 1914, 39: 443-454. doi:  10.1126/science.39.1004.443
    [4] Freedman FB, Johnson JA. Equilibrium and kinetic properties of the Evans blue-albumin system[J]. Am J Physiol, 1969, 216: 675-681. doi:  10.1152/ajplegacy.1969.216.3.675
    [5] Niu G, Lang L, Kiesewetter DO, et al. In Vivo Labeling of Serum Albumin for PET[J]. J Nucl Med, 2014, 55: 1150-1156. doi:  10.2967/jnumed.114.139642
    [6] Wang Y, Lang L, Huang P, et al. In vivo albumin labeling and lymphatic imaging[J]. Proc Natl Acad Sci U S A, 2015, 112: 208-213. doi:  10.1073/pnas.1414821112
    [7] Zhang J, Lang L, Zhu Z, et al. Clinical Translation of an Albumin-Binding PET Radiotracer 68Ga-NEB[J]. J Nucl Med, 2015, 56: 1609-1614. doi:  10.2967/jnumed.115.159640
    [8] Zang J, Liu Q, Sui H, et al. Combined (68)Ga-NOTA-Evans Blue Lymphoscintigraphy and (68)Ga-NOTA-RM26 PET/CT Evaluation of Sentinel Lymph Node Metastasis in Breast Cancer Patients[J]. Bioconjug Chem, 2020, 31: 396-403. doi:  10.1021/acs.bioconjchem.9b00789
    [9] Long X, Zhang J, Zhang D, et al. Microsurgery guided by sequential preoperative lymphography using (68)Ga-NEB PET and MRI in patients with lower-limb lymphedema[J]. Eur J Nucl Med Mol Imaging, 2017, 44: 1501-1510. doi:  10.1007/s00259-017-3676-6
    [10] Zhang W, Wu P, Li F, et al. Potential Applications of Using 68Ga-Evans Blue PET/CT in the Evaluation of Lymphatic Disorder: Preliminary Observations[J]. Clin Nucl Med, 2016, 41: 302-308. doi:  10.1097/RLU.0000000000001171
    [11] Hou G, Jiang Y, Xu W, et al. (68)Ga-NOTA-Evans Blue PET/CT findings in lymphangioleiomyomatosis compared with (99m)TC-ASC lymphoscintigraphy: a prospective study[J]. Orphanet J Rare Dis, 2021, 16: 279. doi:  10.1186/s13023-021-01895-1
    [12] Hou G, Hou B, Jiang Y, et al. 68Ga-NOTA-Evans Blue TOF PET/MR Lymphoscintigraphy Evaluation of the Severity of Lower Limb Lymphedema[J]. Clin Nucl Med, 2019, 44: 439-445. doi:  10.1097/RLU.0000000000002584
    [13] Chen H, Tong X, Lang L, et al. Quantification of Tumor Vascular Permeability and Blood Volume by Positron Emission Tomography[J]. Theranostics, 2017, 7: 2363-2376. doi:  10.7150/thno.19898
    [14] Bombardieri E, Maccauro M, De Deckere E, et al. Nuclear medicine imaging of neuroendocrine tumours[J]. Ann Oncol, 2001, 12 Suppl 2: S51-S61.
    [15] Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors[J]. J Nucl Med, 2018, 59: 66-74. doi:  10.2967/jnumed.117.202275
    [16] Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors[J]. N Engl J Med, 2017, 376: 125-135. doi:  10.1056/NEJMoa1607427
    [17] Tian R, Jacobson O, Niu G, et al. Evans Blue Attachment Enhances Somatostatin Receptor Subtype-2 Imaging and Radiotherapy[J]. Theranostics, 2018, 8: 735-745. doi:  10.7150/thno.23491
    [18] Bandara N, Jacobson O, Mpoy C, et al. Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent[J]. Bioconjug Chem, 2018, 29: 2448-2454. doi:  10.1021/acs.bioconjchem.8b00341
    [19] Zhang J, Wang H, Jacobson O, et al. Safety, Pharmacokinetics and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue (177)Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors[J]. J Nucl Med, 2018, 59: 1699-1705. doi:  10.2967/jnumed.118.209841
    [20] Wang H, Cheng Y, Zhang J, et al. Response to Single Low-dose (177)Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study[J]. Theranostics, 2018, 8: 3308-3316. doi:  10.7150/thno.25919
    [21] Liu Q, Cheng Y, Zang J, et al. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog (177)Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors[J]. Eur J Nucl Med Mol Imaging, 2020, 47: 947-957. doi:  10.1007/s00259-019-04530-1
    [22] Liu Q, Zang J, Sui H, et al. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of (177)Lu-DOTA-EB-TATE[J]. J Nucl Med, 2021, 62: 386-392. doi:  10.2967/jnumed.120.248658
    [23] Bergsma H, Konijnenberg MW, Kam BL, et al. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course[J]. Eur J Nucl Med Mol Imaging, 2016, 43: 453-463. doi:  10.1007/s00259-015-3193-4
    [24] Sabet A, Dautzenberg K, Haslerud T, et al. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine[J]. Eur J Nucl Med Mol Imaging, 2015, 42: 1238-1246. doi:  10.1007/s00259-015-3041-6
    [25] Sabet A, Haslerud T, Pape UF, et al. Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours[J]. Eur J Nucl Med Mol Imaging, 2014, 41: 205-210. doi:  10.1007/s00259-013-2547-z
    [26] Delpassand ES, Samarghandi A, Zamanian S, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience[J]. Pancreas, 2014, 43: 518-525. doi:  10.1097/MPA.0000000000000113
    [27] Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors[J]. Eur J Nucl Med Mol Imaging, 2015, 42: 5-19. doi:  10.1007/s00259-014-2893-5
    [28] Paganelli G, Sansovini M, Ambrosetti A, et al. 177Lu-DOTA-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase Ⅱ study[J]. Eur J Nucl Med Mol Imaging, 2014, 41: 1845-1851. doi:  10.1007/s00259-014-2735-5
    [29] Sabet A, Ezziddin K, Pape UF, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate[J]. J Nucl Med, 2013, 54: 1857-1861. doi:  10.2967/jnumed.112.119347
    [30] Jonathan S, Edward W, Beth C, et al. NETTER-1 Phase Ⅲ in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-DOTATATE: Efficacy and Safety Results[J]. J Nucl Med, 2016, 57: 629.
    [31] Brieau B, Hentic O, Lebtahi R, et al. High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy[J]. Endocr Relat Cancer, 2016, 23: L17-L23. doi:  10.1530/ERC-15-0543
    [32] Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues[J]. Clin Cancer Res, 1997, 3: 81-85.
    [33] Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression[J]. Hum Pathol, 2007, 38: 696-701. doi:  10.1016/j.humpath.2006.11.012
    [34] Wang W, Tavora F, Sharma R, et al. PSMA expression in Schwannoma: a potential clinical mimicker of metastatic prostate carcinoma[J]. Urol Oncol, 2009, 27: 525-528. doi:  10.1016/j.urolonc.2008.04.007
    [35] Marchal C, Redondo M, Padilla M, et al. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia[J]. Histol Histopathol, 2004, 19: 715-718.
    [36] Weineisen M, Schottelius M, Simecek J, et al. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies[J]. J Nucl Med, 2015, 56: 1169-1176. doi:  10.2967/jnumed.115.158550
    [37] Benesova M, Schafer M, Bauder-Wust U, et al. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer[J]. J Nucl Med, 2015, 56: 914-920. doi:  10.2967/jnumed.114.147413
    [38] Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer[J]. N Engl J Med, 2021, 385: 1091-1103. doi:  10.1056/NEJMoa2107322
    [39] Wang Z, Jacobson O, Tian R, et al. Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent (90)Y-DOTA-EB-MCG[J]. Bioconjug Chem, 2018, 29: 2309-2315. doi:  10.1021/acs.bioconjchem.8b00292
    [40] Wang Z, Tian R, Niu G, et al. Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors[J]. Bioconjug Chem, 2018, 29: 3213-3221. doi:  10.1021/acs.bioconjchem.8b00556
    [41] Zang J, Fan X, Wang H, et al. First-in-human study of (177)Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2019, 46: 148-158. doi:  10.1007/s00259-018-4096-y
    [42] Zang J, Liu Q, Sui H, et al. (177)Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer[J]. J Nucl Med, 2020, 61: 1772-1778. doi:  10.2967/jnumed.120.242263
    [43] Hofman MS, Violet J, Hicks RJ, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study[J]. Lancet Oncol, 2018, 19: 825-833. doi:  10.1016/S1470-2045(18)30198-0
  • 加载中
图(1)
计量
  • 文章访问数:  143
  • HTML全文浏览量:  12
  • PDF下载量:  28
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-12-01
  • 录用日期:  2021-12-29
  • 网络出版日期:  2022-01-12
  • 刊出日期:  2022-03-30

目录

    /

    返回文章
    返回